{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T11:03:53Z","timestamp":1777633433794,"version":"3.51.4"},"reference-count":13,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,12,2]],"date-time":"2015-12-02T00:00:00Z","timestamp":1449014400000},"content-version":"vor","delay-in-days":396,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI064927-05"],"award-info":[{"award-number":["AI064927-05"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1038\/jid.2014.248","type":"journal-article","created":{"date-parts":[[2014,6,16]],"date-time":"2014-06-16T13:48:45Z","timestamp":1402926525000},"page":"2839-2842","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["DC-HIL+ CD14+ HLA-DRno\/low Cells Are a Potential Blood Marker and Therapeutic Target for Melanoma"],"prefix":"10.1016","volume":"134","author":[{"given":"Jake","family":"Turrentine","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Sung","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaveh","family":"Nezafati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoichi","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Harker-Murray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Huth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohit R.","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David B.","family":"Harker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoshi","family":"Ariizumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Ponciano D.","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1038\/jid.2014.248_bb0010","series-title":"J Invest Dermatol","article-title":"DC-HIL-expressing myelomonocytic cells are critical promoters of melanoma growth","author":"Chung","year":"2014"},{"key":"10.1038\/jid.2014.248_bb0015","doi-asserted-by":"crossref","first-page":"5778","DOI":"10.4049\/jimmunol.179.9.5778","article-title":"Syndecan-4 mediates the coinhibitory function of DC-HIL on T cell activation","volume":"179","author":"Chung","year":"2007","journal-title":"J Immunol"},{"key":"10.1038\/jid.2014.248_bb0020","doi-asserted-by":"crossref","first-page":"4320","DOI":"10.1182\/blood-2006-11-053769","article-title":"DC-HIL is a negative regulator of T lymphocyte activation","volume":"109","author":"Chung","year":"2007","journal-title":"Blood"},{"key":"10.1038\/jid.2014.248_bb0025","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/imm.12027","article-title":"The DC-HIL ligand syndecan-4 is a negative regulator of T-cell allo-reactivity responsible for graft-versus-host disease","volume":"138","author":"Chung","year":"2013","journal-title":"Immunology"},{"key":"10.1038\/jid.2014.248_bb0030","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00262-008-0523-4","article-title":"Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy","volume":"58","author":"Diaz-Montero","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"10.1038\/jid.2014.248_bb0035","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1200\/JCO.2006.08.5829","article-title":"Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine","volume":"25","author":"Filipazzi","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1038\/jid.2014.248_bb0040","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1172\/JCI29906","article-title":"Myeloid suppressor cells regulate the adaptive immune response to cancer","volume":"116","author":"Frey","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1038\/jid.2014.248_bb0045","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1182\/blood-2006-07-034066","article-title":"CTLA-4 dysregulation of self\/tumor-reactive CD8+ T-cell function is CD4+ T-cell dependent","volume":"108","author":"Gattinoni","year":"2006","journal-title":"Blood"},{"key":"10.1038\/jid.2014.248_bb0050","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma","volume":"369","author":"Hamid","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1038\/jid.2014.248_bb0055","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1038\/jid.2014.248_bb0060","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/j.1600-0625.2008.00779.x","article-title":"Immune modulation by melanoma-derived factors","volume":"17","author":"Ilkovitch","year":"2008","journal-title":"Exp Dermatol"},{"key":"10.1038\/jid.2014.248_bb0065","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","article-title":"Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor","volume":"11","author":"Nishimura","year":"1999","journal-title":"Immunity"},{"key":"10.1038\/jid.2014.248_bb0070","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/1074-7613(95)90125-6","article-title":"Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4","volume":"3","author":"Tivol","year":"1995","journal-title":"Immunity"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X15365362?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X15365362?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T21:09:26Z","timestamp":1743973766000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X15365362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":13,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S0022202X15365362"],"URL":"https:\/\/doi.org\/10.1038\/jid.2014.248","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"DC-HIL+ CD14+ HLA-DRno\/low Cells Are a Potential Blood Marker and Therapeutic Target for Melanoma","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/jid.2014.248","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The Society for Investigative Dermatology, Inc. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}